Search Results
Search for other papers by Andrea Weckman in
Google Scholar
PubMed
Search for other papers by Fabio Rotondo in
Google Scholar
PubMed
Search for other papers by Antonio Di Ieva in
Google Scholar
PubMed
Search for other papers by Luis V Syro in
Google Scholar
PubMed
Search for other papers by Henriett Butz in
Google Scholar
PubMed
Search for other papers by Michael D Cusimano in
Google Scholar
PubMed
Search for other papers by Kalman Kovacs in
Google Scholar
PubMed
malignant pheochromocytoma cells ( Saito et al . 2012 ). Future research is required to elucidate the specifics of autophagy in the different types of adrenal cancer in vitro and in vivo and take full advantage of its therapeutic potential as a target
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Shih-Ping Cheng in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Chien-Liang Liu in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Ming-Jen Chen in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Ming-Nan Chien in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Ching-Hsiang Leung in
Google Scholar
PubMed
Search for other papers by Chi-Hsin Lin in
Google Scholar
PubMed
Search for other papers by Yi-Chiung Hsu in
Google Scholar
PubMed
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Department of Surgery, Division of Endocrinology and Metabolism, Mackay Junior College of Medicine, Department of Pharmacology, Department of Medical Research, Institute of Statistical Science
Search for other papers by Jie-Jen Lee in
Google Scholar
PubMed
CD74, the invariant chain of major histocompatibility complex class II, is also a receptor for macrophage migration inhibitory factor (MIF). CD74 and MIF have been associated with tumor progression and metastasis in hematologic and solid tumors. In this study, we found that 60 and 65% of papillary thyroid cancers were positive for CD74 and MIF immunohistochemical staining respectively. Anaplastic thyroid cancer was negative for MIF, but mostly positive for CD74 expression. Normal thyroid tissue and follicular adenomas were negative for CD74 expression. CD74 expression in papillary thyroid cancer was associated with larger tumor size (P=0.043), extrathyroidal invasion (P=0.021), advanced TNM stage (P=0.006), and higher MACIS score (P=0.026). No clinicopathological parameter was associated with MIF expression. Treatment with anti-CD74 antibody in thyroid cancer cells inhibited cell growth, colony formation, cell migration and invasion, and vascular endothelial growth factor secretion. In contrast, treatment with recombinant MIF induced an increase in cell invasion. Anti-CD74 treatment reduced AKT phosphorylation and stimulated AMPK activation. Our findings suggest that CD74 overexpression in thyroid cancer is associated with advanced tumor stage and may serve as a therapeutic target.
Search for other papers by K W Colston in
Google Scholar
PubMed
Cancer Genetics, Department of Endocrinology, Kolling Institute of Medical Research
Search for other papers by Justin S Gundara in
Google Scholar
PubMed
Search for other papers by JingTing Zhao in
Google Scholar
PubMed
Cancer Genetics, Department of Endocrinology, Kolling Institute of Medical Research
Search for other papers by Bruce G Robinson in
Google Scholar
PubMed
Cancer Genetics, Department of Endocrinology, Kolling Institute of Medical Research
Search for other papers by Stan B Sidhu in
Google Scholar
PubMed
important to cell death as it is to survival. Now that we are gaining a more thorough understanding of the mechanisms underlying autophagy, its relevance to human disease and burgeoning therapeutic potential are being unravelled ( Ding et al . 2008 , Chen
Veterans Affairs‐Northern California Health Care System, Department of Medical Microbiology and Immunology, Biochemistry, Mather, California, USA
Veterans Affairs‐Northern California Health Care System, Department of Medical Microbiology and Immunology, Biochemistry, Mather, California, USA
Search for other papers by Alan P Lombard in
Google Scholar
PubMed
Veterans Affairs‐Northern California Health Care System, Department of Medical Microbiology and Immunology, Biochemistry, Mather, California, USA
Search for other papers by Maria Mudryj in
Google Scholar
PubMed
( Johnson et al . 2008 ). These data argue that one role of the AR in bladder tumorigenesis may be repression of TSP1. Therapeutic potential of targeting the AR in bladder cancer One currently effective treatment for NMIBC is intravesical
Search for other papers by Masaki Shiota in
Google Scholar
PubMed
Search for other papers by Ario Takeuchi in
Google Scholar
PubMed
Departments of, Urology, Anatomic Pathology, Clinical Chemistry and Laboratory Medicine, Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Search for other papers by YooHyun Song in
Google Scholar
PubMed
Search for other papers by Akira Yokomizo in
Google Scholar
PubMed
Search for other papers by Eiji Kashiwagi in
Google Scholar
PubMed
Search for other papers by Takeshi Uchiumi in
Google Scholar
PubMed
Search for other papers by Kentaro Kuroiwa in
Google Scholar
PubMed
Search for other papers by Katsunori Tatsugami in
Google Scholar
PubMed
Search for other papers by Naohiro Fujimoto in
Google Scholar
PubMed
Search for other papers by Yoshinao Oda in
Google Scholar
PubMed
Search for other papers by Seiji Naito in
Google Scholar
PubMed
the roles of YB-1 in androgen/AR signaling and PCa pathology, especially in PCa that progressively becomes castration resistant. Furthermore, we wanted to identify therapeutic potential of targeting YB-1 in PCa. Materials and methods Cell culture Human
Search for other papers by Salma Ben-Salem in
Google Scholar
PubMed
Search for other papers by Varadha Balaji Venkadakrishnan in
Google Scholar
PubMed
Search for other papers by Hannelore V Heemers in
Google Scholar
PubMed
, Feitelson et al. 2015 ). The therapeutic potential of targeting critical cell cycle checkpoints and the possibility of such strategies to overcome cancer treatment resistance and prolong patient survival have also been recognized ( Otto & Sicinski 2017
Search for other papers by Catherine Zabkiewicz in
Google Scholar
PubMed
Search for other papers by Jeyna Resaul in
Google Scholar
PubMed
Search for other papers by Rachel Hargest in
Google Scholar
PubMed
Search for other papers by Wen Guo Jiang in
Google Scholar
PubMed
Search for other papers by Lin Ye in
Google Scholar
PubMed
cancer and therapeutic potential . International Journal of Molecular Medicine 24 591 – 597 . ( doi:10.3892/ijmm_00000269 ) Ye L Bokobza S Li J Moazzam M Chen J Mansel RE Jiang WG 2010 Bone morphogenetic protein-10
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Search for other papers by Samah Rafehi in
Google Scholar
PubMed
Search for other papers by Yudith Ramos Valdes in
Google Scholar
PubMed
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Search for other papers by Monique Bertrand in
Google Scholar
PubMed
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Search for other papers by Jacob McGee in
Google Scholar
PubMed
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Search for other papers by Michel Préfontaine in
Google Scholar
PubMed
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Search for other papers by Akira Sugimoto in
Google Scholar
PubMed
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Search for other papers by Gabriel E DiMattia in
Google Scholar
PubMed
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Translational Ovarian Cancer Research Program, Department of Anatomy and Cell Biology, Department of Biochemistry, Department of Obstetrics and Gynaecology, Department of Oncology, London Regional Cancer Program, 790 Commissioners Road East, Room A4-836, London, Ontario, Canada N6A 4L6
Search for other papers by Trevor G Shepherd in
Google Scholar
PubMed
regulation, as well as the therapeutic potential of targeting this important pathobiological process in late-stage EOC metastasis. Epithelial to mesenchymal transition is a universally accepted phenomenon that occurs in the malignant progression of most if
Search for other papers by Kathrin Zitzmann in
Google Scholar
PubMed
Search for other papers by George Vlotides in
Google Scholar
PubMed
Search for other papers by Stephan Brand in
Google Scholar
PubMed
Search for other papers by Harald Lahm in
Google Scholar
PubMed
Search for other papers by Gerald Spöttl in
Google Scholar
PubMed
Search for other papers by Burkhard Göke in
Google Scholar
PubMed
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
relevant to NET cell survival. To further evaluate the therapeutic potential of isoform-specific Akt inhibition in NET disease, double- and triple-transfection studies were performed. Significantly, the antitumor effect of simultaneous downregulation of Akt